Peter I Croucher

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease
    Peter I Croucher
    Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, United Kingdom
    Cancer 97:818-24. 2003
  2. ncbi request reprint Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
    Peter I Croucher
    Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom
    J Bone Miner Res 18:482-92. 2003
  3. ncbi request reprint Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo
    Claire M Edwards
    Institute of Musculoskeletal Sciences and the Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford, United Kingdom
    Int J Cancer 120:1657-63. 2007
  4. ncbi request reprint Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells
    Claire M Shipman
    Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford OX3 7LD, United Kingdom
    Cancer Res 63:912-6. 2003
  5. ncbi request reprint Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
    Ingunn Holen
    Bone Oncology Group, Divisions of Clinical Sciences and Genomic Medicine, Medical School, University of Sheffield, Sheffield, UK
    Cancer Res 62:1619-23. 2002
  6. ncbi request reprint Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma
    Karin Vanderkerken
    Department of Hematology and Immunology, Vrije Universiteit Brussel VUB, Brussels, Belgium
    Cancer Res 67:4572-7. 2007
  7. ncbi request reprint An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma
    Deborah J Heath
    Academic Unit of Bone Biology, Division of Clinical Sciences South, University of Sheffield Medical School, Beech Hill Road, Sheffield, Yorkshire, United Kingdom
    Cancer Res 67:202-8. 2007
  8. ncbi request reprint Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
    Evangelos Terpos
    Department of Haematology and Medical Research, General Airforce Hospital, Athens, Greece
    Br J Haematol 135:688-92. 2006
  9. pmc ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin
    Abdullah Karadag
    Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
    Blood 107:3271-8. 2006
  10. ncbi request reprint Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Ingunn Holen
    Bone Oncology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 92:207-15. 2005

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease
    Peter I Croucher
    Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, United Kingdom
    Cancer 97:818-24. 2003
    ....
  2. ncbi request reprint Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
    Peter I Croucher
    Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom
    J Bone Miner Res 18:482-92. 2003
    ..These data show that zoledronic acid is able to prevent the development of osteolytic bone disease, decrease tumor burden in bone, and increase survival in a model of established myeloma...
  3. ncbi request reprint Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo
    Claire M Edwards
    Institute of Musculoskeletal Sciences and the Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford, United Kingdom
    Int J Cancer 120:1657-63. 2007
    ..The use of bisphosphonate esters such as Apomine represents a novel therapeutic approach in the treatment of myeloma and, indirectly, the associated bone disease...
  4. ncbi request reprint Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells
    Claire M Shipman
    Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford OX3 7LD, United Kingdom
    Cancer Res 63:912-6. 2003
    ..These observations suggest that OPG may function as a paracrine survival factor in the bone marrow microenvironment in multiple myeloma...
  5. ncbi request reprint Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
    Ingunn Holen
    Bone Oncology Group, Divisions of Clinical Sciences and Genomic Medicine, Medical School, University of Sheffield, Sheffield, UK
    Cancer Res 62:1619-23. 2002
    ..These observations suggest that prostate cancer-derived OPG may be an important survival factor in hormone-resistant prostate cancer cells...
  6. ncbi request reprint Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma
    Karin Vanderkerken
    Department of Hematology and Immunology, Vrije Universiteit Brussel VUB, Brussels, Belgium
    Cancer Res 67:4572-7. 2007
    ..Together, these data show that targeting p38alpha MAPK with SCIO-469 decreases myeloma burden in vivo, in addition to preventing the development of myeloma bone disease...
  7. ncbi request reprint An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma
    Deborah J Heath
    Academic Unit of Bone Biology, Division of Clinical Sciences South, University of Sheffield Medical School, Beech Hill Road, Sheffield, Yorkshire, United Kingdom
    Cancer Res 67:202-8. 2007
    ..Cancer Res 2007;67(1):202-8]...
  8. ncbi request reprint Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
    Evangelos Terpos
    Department of Haematology and Medical Research, General Airforce Hospital, Athens, Greece
    Br J Haematol 135:688-92. 2006
    ..This is the first study showing that bortezomib reduces DKK-1 and RANKL serum levels, leading to the normalisation of bone remodelling in relapsed myeloma...
  9. pmc ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin
    Abdullah Karadag
    Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, United Kingdom
    Blood 107:3271-8. 2006
    ..01). These data demonstrate that ADAM-9, expressed by myeloma cells, stimulates IL-6 production in hOBs by binding the alpha(v)beta5 integrin. This may have important consequences for the growth and survival of myeloma cells in bone...
  10. ncbi request reprint Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Ingunn Holen
    Bone Oncology Group, Division of Genomic Medicine, University of Sheffield, Sheffield, UK
    Breast Cancer Res Treat 92:207-15. 2005
    ..To our knowledge these results are the first to demonstrate that OPG can act as an endocrine survival factor for breast cancer cells, as well as reporting the expression patterns of OPG in a large cohort of human breast tumours...
  11. pmc Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model
    Els Van Valckenborgh
    Department Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium
    Am J Pathol 165:869-78. 2004
    ..The direct role of MMPs in these different processes was confirmed by in vitro experiments. All these results support the multifunctional role of MMPs in the development of multiple myeloma...
  12. ncbi request reprint Evidence of a role for RANKL in the development of myeloma bone disease
    Evy De Leenheer
    Bone Biology Group, G Floor, Division of Clinical Sciences, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Curr Opin Pharmacol 4:340-6. 2004
    ..Intriguingly, inhibiting osteoclast formation and bone resorption, and altering the bone marrow microenvironment, results in an indirect anti-myeloma effect...
  13. ncbi request reprint Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer
    Colby L Eaton
    Academic Urology Unit, University of Sheffield Medical School, Sheffield, United Kingdom
    Prostate 59:304-10. 2004
    ..In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated patients receiving androgen ablation...
  14. ncbi request reprint Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
    Marianna C Politou
    Department of Hematology, Faculty of Medicine, Hammersmith Hospital, Imperial College, London, United Kingdom
    Int J Cancer 119:1728-31. 2006
    ..These results could provide the basis for developing agents that block DKK-1, thus restoring osteoblast function and counteracting the increased osteoclastogenesis observed in myeloma...
  15. ncbi request reprint Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways
    Srdjan Vitovski
    Section of Musculoskeletal Science, University of Sheffield School of Medical and Biomedical Sciences, Beech Hill Road, Sheffield, Yorkshire S10 2RX, United Kingdom
    J Biol Chem 282:31601-9. 2007
    ..This highlights the pivotal role of OPG in regulating the biology of both RANKL and TRAIL...